Objective To develop and verify a method for detection of complement-dependent cytotoxicity(CDC) of recombinant humanized anti-CD52 monoclonal antibody(Mc Ab). Methods Human lymphoma cells in which CD52 antigen was expressed were added with serially diluted recombinant humanized anti-CD52 Mc Ab and the freeze-dried complement, and incubated at 37 ℃ in 5% CO_2 incubator for 3 h. The number of viable target cells was determined by ATP chromogenic method. The test condition was optimized, and the developed met...